BioMedNewsBreaks

ThursdayOct 01, 2026 11:56 am

BioMedNewsBreaks – HealthLynked Corp. (OTCQB: HLYK) Selects DRCARE247 as Telemedicine Partner

HealthLynked (OTCQB: HLYK) , a healthcare technology company focused on AI-powered patient engagement, care coordination and provider connectivity, selected DRCARE247 as its telemedicine partner. The partnership will integrate virtual care into the HealthLynked mobile application and website, allowing users to move from AI-powered health guidance to provider discovery, appointment scheduling, virtual consultations and medical record management within a single platform. HealthLynked expects to begin launching the integrated telemedicine platform in selected geographic regions over the next three months, followed by expansion into additional U.S. markets, subject to provider availability and applicable state requirements. The integration is expected to work alongside…

Continue Reading

ThursdayOct 01, 2026 9:00 am

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Closes $4 Million Registered Direct Offering

Lantern Pharma (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, announced the closing of its previously announced registered direct offering of 3,669,725 shares of common stock, or pre-funded warrants in lieu thereof, at $1.09 per share. The offering generated approximately $4 million in gross proceeds before fees and expenses. In a concurrent private placement, Lantern issued unregistered warrants to purchase up to 3,669,725 shares at an exercise price of $1.09 per share, potentially providing an additional approximately $4 million in gross proceeds if fully exercised for cash. The company intends…

Continue Reading

WednesdaySep 30, 2026 3:50 pm

BioMedNewsBreaks — Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H) Preps ONC010 for Clinical Translation

Disseminated on behalf of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H) and may include paid advertising. Onco-Innovations (CBOE CA: ONCO)(OTCQB: ONNVF)(FSE: W1H) is advancing its preclinical oncology candidate ONC010, a nanoparticle-encapsulated PNKP inhibitor designed to disrupt DNA-repair mechanisms involved in cancer survival and treatment resistance, while building the manufacturing, regulatory and financial infrastructure needed for clinical development. The company reports completing a 300-gram API scale-up with approximately 99.3% purity, expanding manufacturing capabilities through a partnership with Nanosoft Polymers, and progressing metabolism, analytical, licensing and other IND-enabling activities. It has also arranged approximately CAD$5 million in institutional financing, to be released through 18 monthly tranches, to…

Continue Reading

WednesdaySep 30, 2026 10:39 am

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Co-Founder Discusses Lucid-MS Phase 2 Program, unbuzzd(TM) in BioMedWire Podcast 

Quantum BioPharma (NASDAQ: QNTM) Co-Founder and Executive Co-Chair Anthony Durkacz returned to The BioMedWire Podcast to discuss the company’s Lucid-MS drug candidate, which is advancing to a Phase 2 trial in multiple sclerosis patients, as well as the development and commercial opportunity surrounding unbuzzd(TM). Durkacz said Lucid-MS targets myelin and that the upcoming trial will mark the first time the drug is tested in patients with multiple sclerosis. He also highlighted clinical results for unbuzzd(TM), which is designed to accelerate alcohol metabolism, and said Quantum BioPharma owns approximately 20% of the company behind the product and has a 7% royalty…

Continue Reading

TuesdaySep 29, 2026 2:55 pm

BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Moves VXA-222 Bispecific ADC to Next Development Stage

VERAXA Biotech (NASDAQ: VRXA) has advanced its VXA-222 bispecific antibody-drug conjugate (“ADC”) program beyond the initial discovery phase following the completion of its collaboration with OmniAb, with the company now planning to engineer the final candidate using its antibody-engineering, linker and conjugation technologies and conduct in vitro and in vivo preclinical studies. VXA-222 employs an “AND-gate” design intended to recognize two tumor-associated antigens simultaneously, potentially increasing selectivity for cancer cells, while VERAXA continues developing a broader oncology pipeline spanning ADCs, T-cell engagers and other engineered antibody formats. The company has also filed its first patents covering its BiTAC-TCE and BiTAC-ADC…

Continue Reading

TuesdaySep 29, 2026 2:11 pm

BioMedNewsBreaks — Earth Science Tech Inc. (ETST) Adds California Hub to Growing Pharmacy Network

Earth Science Tech (OTC: ETST) recently continued its expansion in the healthcare, pharmacy and telemedicine sectors with the acquisition of Meduvo LLC, a California-based compounding pharmacy operating from a 2,000-square-foot facility in La Verne. The acquisition expands ETST’s pharmacy network to 34 U.S. jurisdictions and gives the company a West Coast operational hub, complementing its existing compounding pharmacy subsidiaries, RxCompoundStore.com and Mister Meds. The company plans to upgrade Meduvo’s facility to meet sterile-compounding requirements, with management targeting regulatory certification by the end of 2028. The acquisition fits ETST’s broader strategy of expanding its geographic reach, integrating telemedicine with pharmacy fulfillment…

Continue Reading

TuesdaySep 29, 2026 9:30 am

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Announces $4 Million Registered Direct Offering

Lantern Pharma (NASDAQ: LTRN) announced a definitive agreement for the purchase and sale of 3,669,725 shares of common stock, or pre-funded warrants in lieu thereof, at $1.09 per share in a registered direct offering expected to generate approximately $4 million in gross proceeds. In a concurrent private placement, the company will issue unregistered warrants to purchase up to 3,669,725 additional shares at an exercise price of $1.09 per share, potentially generating approximately $4 million in additional gross proceeds if fully exercised for cash. The offering is expected to close on or about Sept. 30, 2026, subject to customary closing conditions,…

Continue Reading

ThursdaySep 24, 2026 11:52 am

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Advances Oncology Pipeline Following Nasdaq Listing as Xlife Sciences (SIX: XLS) Reports First-Half Progress

VERAXA Biotech (NASDAQ: VRXA) is shifting its focus to advancing its oncology pipeline and implementing industrial partnerships for its technology platforms and products following the completion of its business combination and commencement of Nasdaq trading in June 2026. Xlife Sciences AG (SIX: XLS) said VERAXA secured a financing base to support its next development steps and remains an important part of its portfolio strategy. Xlife Sciences also reported operational and scientific progress across its portfolio during the first half of 2026, including developments at x-kidney diagnostics, saniva diagnostics, Axenoll, FUSE-AI and inflamed pharma. The portfolio comprises 416 patents and patent…

Continue Reading

ThursdaySep 24, 2026 9:40 am

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Licensee Unbuzzd Wellness Appoints Michael “Zappy” Zapolin CEO

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) announced that its licensee, Unbuzzd Wellness Inc., appointed Michael Zapolin as CEO. Zapolin’s mandate includes financing and listing Unbuzzd on a stock exchange, followed by a nationwide commercial marketing and product rollout in the United States. Former CEO Richard Buzbuzian is assisting with the transition to a publicly listed company, which is scheduled to go effective in the next quarter. Unbuzzd markets unbuzzd(TM), a beverage designed to accelerate alcohol metabolism, restore mental clarity and reduce hangover symptoms. The company said…

Continue Reading

WednesdaySep 23, 2026 11:53 am

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO)(OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) and Redwood AI (CSE: AIRX) (OTCQB: RDWCF) Awarded Digital Health Innovation Fund Grant for AI-Driven Oncology Platform 

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising.  Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) and Redwood AI (CSE: AIRX) (OTCQB: RDWCF), together with Canada's Michael Smith Genome Sciences Centre and Centre de recherche du CHU de Québec-Université Laval, were awarded a competitive Digital Health Innovation Fund grant administered by the Terry Fox Research Institute to support development of Onco SynoGraph AI-driven oncology platform. The reimbursement-based grant covers up to 25% of an estimated $3.5 million project budget. The project will advance SynoGraph using federated learning and causal AI to…

Continue Reading